Skip to content

Clinical study of topical application of spearhead viper haemagglutinin to reduce perioperative blood loss in total hip arthroplasty: a prospective randomised controlled trial

Clinical study of topical application of spearhead viper haemagglutinin to reduce perioperative blood loss in total hip arthroplasty: a prospective randomised controlled trial

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084303
Enrollment
Unknown
Registered
2024-05-14
Start date
2024-05-15
Completion date
Unknown
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Femoral head necrosis/hip osteoarthritis

Interventions

Batuting Formation
:Pattriptine is used locally in hip arthroplasty
Tranexamic acid group:Tranexamic acid is used locally in hip arthroplasty

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients with ASA grade I-III who can tolerate surgery; (2) no liver, kidney and coagulation system diseases; (3) Preoperative hemoglobin above 100g/L; (4) Normal coagulation function; (5) Participants had no prior history of hip injury, fracture or surgery; (6) Patients with femoral head necrosis and hip osteoarthritis. (7) The participants themselves and their families are willing to accept this study and sign the informed consent before surgery.

Exclusion criteria

Exclusion criteria: (1) Those who have a tendency to bleed through laboratory examination; (2) Allergy to hemagglutinin and tranexamic acid; (3) Patients who take anticoagulation or drugs that affect coagulation function two weeks before surgery; (4) Liver and kidney insufficiency; (5) Patients with coagulation system diseases; (6) Patients with femoral neck fracture and other traumatic fracture bleeding. (7) Those who refuse to study this subject and refuse to sign the treatment consent.

Design outcomes

Primary

MeasureTime frame
blood routine examination;coagulation function;inflammatory factor;Amount of bleeding ;

Secondary

MeasureTime frame
thrombus of lower extremity veins;postoperative wound infection;pulmonary embolism;Blood transfusions;

Countries

China

Contacts

Public ContactShixiaojun

West China Hospital of Sichuan University

Shixjoint@scu.edu.cn+86 189 8060 6872

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026